BIOMAT Database Logo BIOMAT Database Logo

[LDL apheresis--an effective treatment of homozygous familial hypercholesterolemia]. 1990

R Kauppinen-Mäkelin, and V Koivisto, and K S Virtanen, and M R Taskinen, and T Miettinen
HYKS:n II sisätautien klinikka, Helsinki, Finland.

UI MeSH Term Description Entries
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D001781 Blood Component Removal Any procedure in which blood is withdrawn from a donor, a portion is separated and retained, at the same time the remainder is returned to the donor. Apheresis,Pheresis,Aphereses,Blood Component Removals,Phereses,Removal, Blood Component
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D005260 Female Females
D006720 Homozygote An individual in which both alleles at a given locus are identical. Homozygotes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006938 Hyperlipoproteinemia Type II A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). Hyperbetalipoproteinemia,Hypercholesterolemia, Essential,Hypercholesterolemia, Familial,Apolipoprotein B-100, Familial Defective,Apolipoprotein B-100, Familial Ligand-Defective,Familial Combined Hyperlipoproteinemia,Hyper-Low Density Lipoproteinemia,Hyper-Low-Density-Lipoproteinemia,Hyper-beta-Lipoproteinemia,Hypercholesterolemia, Autosomal Dominant,Hypercholesterolemia, Autosomal Dominant, Type B,Hypercholesterolemic Xanthomatosis, Familial,Hyperlipoproteinemia Type 2,Hyperlipoproteinemia Type IIa,Hyperlipoproteinemia Type IIb,Hyperlipoproteinemia, Type II,Hyperlipoproteinemia, Type IIa,LDL Receptor Disorder,Apolipoprotein B 100, Familial Defective,Apolipoprotein B 100, Familial Ligand Defective,Autosomal Dominant Hypercholesterolemia,Autosomal Dominant Hypercholesterolemias,Combined Hyperlipoproteinemia, Familial,Combined Hyperlipoproteinemias, Familial,Density Lipoproteinemia, Hyper-Low,Density Lipoproteinemias, Hyper-Low,Disorder, LDL Receptor,Disorders, LDL Receptor,Dominant Hypercholesterolemia, Autosomal,Dominant Hypercholesterolemias, Autosomal,Essential Hypercholesterolemia,Essential Hypercholesterolemias,Familial Combined Hyperlipoproteinemias,Familial Hypercholesterolemia,Familial Hypercholesterolemias,Familial Hypercholesterolemic Xanthomatoses,Familial Hypercholesterolemic Xanthomatosis,Hyper Low Density Lipoproteinemia,Hyper beta Lipoproteinemia,Hyper-Low Density Lipoproteinemias,Hyper-Low-Density-Lipoproteinemias,Hyper-beta-Lipoproteinemias,Hyperbetalipoproteinemias,Hypercholesterolemias, Autosomal Dominant,Hypercholesterolemias, Essential,Hypercholesterolemias, Familial,Hypercholesterolemic Xanthomatoses, Familial,Hyperlipoproteinemia Type 2s,Hyperlipoproteinemia Type IIas,Hyperlipoproteinemia Type IIbs,Hyperlipoproteinemia Type IIs,Hyperlipoproteinemia, Familial Combined,Hyperlipoproteinemias, Familial Combined,Hyperlipoproteinemias, Type II,Hyperlipoproteinemias, Type IIa,LDL Receptor Disorders,Lipoproteinemia, Hyper-Low Density,Lipoproteinemias, Hyper-Low Density,Receptor Disorder, LDL,Receptor Disorders, LDL,Type 2, Hyperlipoproteinemia,Type II Hyperlipoproteinemia,Type II Hyperlipoproteinemias,Type IIa Hyperlipoproteinemia,Type IIa Hyperlipoproteinemias,Xanthomatoses, Familial Hypercholesterolemic,Xanthomatosis, Familial Hypercholesterolemic
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

R Kauppinen-Mäkelin, and V Koivisto, and K S Virtanen, and M R Taskinen, and T Miettinen
[LDL oxidation in homozygous familial hypercholesterolemia: effects of selective LDL-apheresis treatment].
May 1996, Cardiologia (Rome, Italy),
R Kauppinen-Mäkelin, and V Koivisto, and K S Virtanen, and M R Taskinen, and T Miettinen
Treatment of homozygous familial hypercholesterolemia by plasma exchange and LDL-apheresis.
October 1993, Transfusion science,
R Kauppinen-Mäkelin, and V Koivisto, and K S Virtanen, and M R Taskinen, and T Miettinen
Pregnancy in homozygous familial hypercholesterolemia--Importance of LDL-apheresis.
May 2015, Atherosclerosis. Supplements,
R Kauppinen-Mäkelin, and V Koivisto, and K S Virtanen, and M R Taskinen, and T Miettinen
LDL-apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich experience.
December 2009, Atherosclerosis. Supplements,
R Kauppinen-Mäkelin, and V Koivisto, and K S Virtanen, and M R Taskinen, and T Miettinen
Role of LDL apheresis in a case of homozygous familial hypercholesterolemia.
January 2019, Drug discoveries & therapeutics,
R Kauppinen-Mäkelin, and V Koivisto, and K S Virtanen, and M R Taskinen, and T Miettinen
[LDL-apheresis in the treatment familial hypercholesterolemia].
November 2014, Vnitrni lekarstvi,
R Kauppinen-Mäkelin, and V Koivisto, and K S Virtanen, and M R Taskinen, and T Miettinen
[Serum lipoprotein (a) levels during treatment with LDL apheresis for homozygous familial hypercholesterolemia].
October 1992, Medicina clinica,
R Kauppinen-Mäkelin, and V Koivisto, and K S Virtanen, and M R Taskinen, and T Miettinen
[Treatment of homozygous familial hypercholesterolemia with LDL-apheresis on a 4-year-old child].
December 2009, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
R Kauppinen-Mäkelin, and V Koivisto, and K S Virtanen, and M R Taskinen, and T Miettinen
[LDL apheresis in the treatment of familial hypercholesterolemia].
October 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir,
R Kauppinen-Mäkelin, and V Koivisto, and K S Virtanen, and M R Taskinen, and T Miettinen
[LDL-apheresis in the treatment of familial hypercholesterolemia].
January 1985, La Ricerca in clinica e in laboratorio,
Copied contents to your clipboard!